Comment on Zhu et al, page 1494

### Polyphosphates rock! A role in thrombosis?

**Douglas M. Monroe**

**University of North Carolina at Chapel Hill**

In this issue of *Blood*, Zhu et al have established, in human blood, that factor XIa and polyphosphate make significant contributions to thrombus formation. This makes these molecules good targets for therapeutic intervention.

The emphasis on human blood is important, as many thrombosis studies have been conducted in mice. Mouse studies take advantage of 2 things: (1) robust imaging tools that allow in vivo thrombus formation to be monitored and quantified, and (2) genetic manipulation of the mice to generate mechanistic information. However, there are data to suggest that mice may have significant differences in thrombus formation relative to primates and humans. Thus, it is critical to test potential antithrombotic mechanisms in human blood.

Directed antithrombics in current use are targeted inhibitors of thrombin and factor Xa. However, Zhu et al went in a different direction and studied the role of factor XI. Factor XI is an especially interesting molecule, because it lies at the critical junction of the classical contact pathway (factor XIIa and high-molecular-weight kininogen activation of factor XI) and the platelet-driven thrombin feedback amplification loop. This feedback was suggested by studies showing that sulfated glycans could promote thrombin activation of factor XI. Subsequent work provided a physiological basis by showing that activated platelets could sustain this reaction. The laboratory of Dr Morrissey established the mechanism of this activation by showing that polyphosphate released from platelet-dense granules was the agent that promoted thrombin activation of factor XI.

A logical extension of those studies on the biochemistry of polyphosphate is to examine the antithrombotic properties of agents that target factor XI and polyphosphate. In this study, Zhu et al used sophisticated flow models of thrombosis to generate nuanced results. They included the role of flow by passing the blood over collagen to give platelet adherence and contact activation. They studied the results of 3 inhibitors: (1) an antibody that selectively blocks factor XIIa activation of factor XI (without interfering with thrombin activation of factor XI), (2) an antibody that blocks factor XIa activation of factor IX, and (3) a compound that binds and neutralizes polyphosphate (see figure). With these 3 inhibitors, they used low, medium, and high tissue factor to modulate the procoagulant signal. The study is complicated by the fact that merely drawing blood can result in nonphysiological contact activation. Zhu et al get around this by using a small amount of thrombin (Ila) that binds to polyphosphate and activates factor XI to factor Xa to drive thrombin (Ila) generation and fibrin formation. PolyP, polyphosphate; TF, tissue factor.

A broad overview of the components that are subject to inhibition under 3 sets of conditions (many of the coagulation steps are omitted). For an accurate analysis, see supplemental Figure 6 in the article by Zhu et al that begins on page 1494. Platelets adhere to collagen and are partially activated releasing polyphosphate from dense granules (dark spots on the platelets). During fibrin formation, fibrin structure is altered by association with polyphosphate, leading to a structure that is more resistant to lysis. (A) Factor XII is activated to factor Xlla. Factor Xlla activates factor XI to factor Xla, which activates factor IX to factor IXa, leading to thrombin (Ila) generation and fibrin formation. (B) Tissue factor initiates the generation of a small amount of thrombin (Ila) that binds to polyphosphate and activates factor X to factor Xla. Additional factor Xla is generated from factor Xlla by contact activation. Factor Xla activates factor IX to factor IXa, leading to thrombin (Ila) generation and fibrin formation. (C) At high tissue factor, sufficient factor IXa is activated to factor Xla to drive thrombin (Ila) generation and fibrin formation. PolyP, polyphosphate; TF, tissue factor.
was specific for thrombin generation and fibrin formation.

Perhaps more interesting, Zhu et al showed that polyphosphate played a role in more than just thrombin generation through feedback activation of factor XI. Polyphosphate directly interacted with fibrin in a way that made the thrombus less susceptible to lysis by fibrinolytic agents. Blocking polyphosphate reduced thrombus stability and increased lysis of the fibrin clot. All of this suggests that polyphosphate is an intriguing target for antithrombotic agents. Such an antithrombotic would not only reduce thrombin generation but also alter fibrin structure to promote lysis of any thrombus that does form.

One of the holy grails of antithrombotic therapy is to have agents that are effective without increasing the risk of bleeding. Zhu et al discuss the data suggesting that the contribution of the contact pathway to hemostasis is to augment the existing platelet-driven thrombin generation. In this study, Zhu et al significantly advance our understanding of possible contributions of the contact pathway to thrombus formation. If, as this study suggests, factor XI and polyphosphate have a greater contribution to thrombus formation than hemostasis in human blood, then those molecules make appealing targets for novel antithrombotic agents.

Conflict-of-interest disclosure: The author declares no competing financial interests.

REFERENCES

DOI 10.1182/blood-2015-07-657148
© 2015 by The American Society of Hematology

Comment on Wikstrom et al, page 1503

Does GVHD make amateurs out of professional APCs?

Alan M. Hanash MEMORIAL SLOAN KETTING CANCER CENTER

In this issue of Blood, Wikstrom and colleagues highlight antigen-presenting cell (APC) dysfunction as a potential cause of impaired antiviral immunity in graft-versus-host disease (GVHD).1

Along with malignant relapse and GVHD, posttransplant immunodeficiency and infections represent major barriers to successful allogeneic hematopoietic transplantation. Cytomegalovirus (CMV) infection in particular is a frequent cause of morbidity posttransplant, especially for recipients of T-cell–depleted and umbilical cord blood allografts as well as patients with GVHD.2,3 GVHD is often viewed as a central problem because it necessitates treatment with corticosteroids and can also lead to thymic damage, both of which compromise immune recovery and may increase the risks of infection and relapse.4–6

Although impaired antimicrobial T-cell immunity posttransplant is frequently attributed to reduced T-cell recovery, competent adaptive immune responses require several steps, including T-cell activation by APCs such as dendritic cells (DCs). Moreover, there is a growing awareness that other immune cells besides αβ T cells contribute to anti-CMV immunity posttransplant, and the pathophysiology of CMV reactivation involves more than just T-cell deficiency.7 Furthermore, in addition to impaired T-cell immune reconstitution, patients at risk for CMV infection due to GVHD have also been found to demonstrate reduced DC reconstitution, and CMV infection itself can impair DC function.8,9

To evaluate the function of DCs during viral infection posttransplant, Wikstrom and colleagues turned to experimental mouse models of bone marrow transplantation (BMT), which have proven to be tremendously valuable to the field of hematopoietic transplantation since its inception. First, the authors discovered that allogeneic BMT recipients with GVHD were profoundly more susceptible to infection with murine CMV (MCMV) posttransplant than syngeneic BMT recipients, and MCMV-infected mice with GVHD demonstrated more severe hepatic necrosis than uninfected mice with GVHD or infected mice without GVHD. The authors also found that there was reduced expansion of MCMV-reactive CD8+ T cells in syngeneic transplant recipients after DC depletion, demonstrating the importance of DCs for generating an anti-MCMV immune response post-BMT.

Evaluating MCMV-reactive T cells after allogeneic BMT, the authors found that GVHD appeared to have an effect similar to DC depletion after syngeneic BMT. There was reduced expansion of MCMV-reactive CD8+ T cells in allogeneic transplant recipients with GVHD. There were also fewer splenic CD8α+ and CD11b+ DCs in infected mice with GVHD, the splenic DCs that were present in mice with GVHD were less likely to be infected with MCMV, and these DCs demonstrated reduced expression of the costimulatory molecules CD40 and CD86. These defects could be overcome by transfer of MCMV-specific transgenic T cells or by transfer of polyclonal T cells from donor mice that had been exposed to MCMV.

The findings of the authors highlight the importance of DC function for mounting effective antiviral T-cell responses posttransplant. Interestingly, although MCMV–specific transgenic T cells appeared to expand less in mice with GVHD, they remained effective in controlling the virus. These were naïve T cells, suggesting that APC-related defects posttransplant can be overcome if there is an adequate MCMV–reactive T-cell pool. However, this APC...
Polyphosphates rock! A role in thrombosis?
Dougald M. Monroe